Skip to main content

Advertisement

SpringerLink
Log in

Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF (2017) New insight into the biology, risk stratification, and targeted treatment of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book 37:480–494

    Article  PubMed  Google Scholar 

  2. Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P, Savvulidi F, Necas E, Hajkova H, Haskovec C, Cermak J, Krivjanska M, Trneny M, Laslo P, Jonasova A, Stopka T (2012) 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 26:1804–1811

    Article  CAS  PubMed  Google Scholar 

  3. Laricchia-Robbio L, Premanand K, Rinaldi CR et al (2009) EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 69:1633–1642

    Article  CAS  PubMed  Google Scholar 

  4. Xiaorong G, Quteba E, Reda ZM et al (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest. https://doi.org/10.1172/JCI97117

  5. Imoto A, Okada M, Okazaki T, Kitasato H, Harigae H, Takahashi S (2010) Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells. J Biol Chem 285:10300–10309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Van der Weyden L, Rust AG, McIntyre RE et al (2013) Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene 32:397–402

    Article  CAS  PubMed  Google Scholar 

  7. Rasmussen MH, Wang B, Wabl M, Nielsen AL, Pedersen FS (2009) Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis. Nucleic Acids Res 37:4657–4671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sønderby CK, Winther O, Rapin N, Porse BT (2016) BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res 44:D917–D924

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Rachael Simpson for her contribution towards some of the experimental assays.

Funding

This study was funded by Celgene Pharma.

Author information

Authors and Affiliations

  1. School of Life Sciences, College of Science, Joseph Banks Laboratories, University of Lincoln, Green Lane, Lincoln, Lincolnshire, LN6 7DL, UK

    Kristian Boasman, Matthew James Simmonds & Ciro Roberto Rinaldi

  2. School of Biological Sciences, Queen’s University Belfast Medical Biology Centre, Belfast, UK

    Ciaren Graham

  3. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

    Yogen Saunthararajah

Authors
  1. Kristian Boasman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew James Simmonds
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ciaren Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yogen Saunthararajah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ciro Roberto Rinaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ciro Roberto Rinaldi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boasman, K., Simmonds, M.J., Graham, C. et al. Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation. Ann Hematol 98, 1529–1531 (2019). https://doi.org/10.1007/s00277-019-03627-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03627-9

Search

Navigation